William Blair Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Stock analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for shares of Nkarta in a research report issued to clients and investors on Thursday, March 27th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.44) per share for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06.

A number of other research analysts also recently issued reports on NKTX. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Nkarta in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday. Finally, Stifel Nicolaus lowered their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $14.86.

Nkarta Stock Performance

NKTX opened at $2.00 on Monday. The stock’s 50 day moving average price is $1.99 and its 200-day moving average price is $2.82. Nkarta has a 52-week low of $1.31 and a 52-week high of $11.84. The stock has a market capitalization of $141.92 million, a PE ratio of -1.06 and a beta of 0.90.

Hedge Funds Weigh In On Nkarta

A number of hedge funds have recently added to or reduced their stakes in NKTX. Invesco Ltd. purchased a new stake in Nkarta during the 4th quarter valued at $30,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Nkarta during the fourth quarter valued at $31,000. Erste Asset Management GmbH purchased a new stake in shares of Nkarta during the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new stake in Nkarta in the 4th quarter worth about $37,000. Finally, ProShare Advisors LLC purchased a new position in Nkarta in the 4th quarter worth about $45,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.70% of the stock is owned by company insiders.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.